Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on aTyr Pharma (LIFE – Research Report). The associated price target is $35.00.
Joseph Pantginis’s Buy rating for aTyr Pharma is based on several key factors. The primary reason is the promise shown by the company’s drug, efzofitimod, in treating rheumatoid arthritis (RA) and RA-associated interstitial lung disease (ILD). The drug’s potential was highlighted in new preclinical data presented at the American College of Rheumatology (ACR) Convergence 2023. In particular, efzofitimod demonstrated efficacy in reducing immune cell populations in the lungs and significantly alleviating lung fibrosis induced by RA.
Furthermore, Pantginis commends the company’s continuous efforts to explore and expand the therapeutic applications of efzofitimod. It is noted that the drug’s versatility and potential extends beyond its original respiratory indications. Although the management currently has no plans to venture into RA, the data supports the possibility of efzofitimod playing a broader role in addressing various inflammatory conditions. aTyr is staying focused on developing efzofitimod in the Phase 3 EFZO-FIT study in patients with pulmonary sarcoidosis, and the Phase 2 EFZO-CONNECT study, in patients with systemic sclerosis (SSc-ILD). Both of these trials are progressing well, contributing to the optimistic outlook for the stock.
According to TipRanks, Pantginis is an analyst with an average return of -14.8% and a 25.40% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, aTyr Pharma, and PDS Biotechnology.
In another report released on November 10, Piper Sandler also maintained a Buy rating on the stock with a $20.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
aTyr Pharma (LIFE) Company Description:
aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Read More on LIFE:
- aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
- aTyr Pharma files $300M mixed securities shelf
- aTyr Pharma reports Q3 EPS (20c), consensus (23c)
- aTyr Pharma to Present at November Investor Conferences
- aTyr Pharma announces dosing of first patient in Phase 2 EFZO-CONNECT study
